Development of iPSC-derived immune cell-based cancer immunotherapy, from the aspect of non-clinical safety tests

DOI
  • KANEKO Shin
    Center for iPS cell Research and Application (CiRA), Kyoto University

Bibliographic Information

Other Title
  • iPS 細胞由来免疫細胞の毒性評価経験から

Abstract

<p>As an AMED supported project, we are developing cancer immunotherapy using immune cells derived from HLA haplotype-identical allogeneic iPS cells. Specifically, we are working on the development of iCAR-ILC / NK therapy using NK cells, which are classified as innate lymphoid cells. At this symposium, I would like to introduce the basics of iCAR-ILC / NK therapy and our efforts toward clinical trials including non-clinical safety tests.</p>

Journal

Details 詳細情報について

  • CRID
    1390289011245674368
  • NII Article ID
    130008073893
  • DOI
    10.14869/toxpt.48.1.0_s27-3
  • Text Lang
    ja
  • Data Source
    • JaLC
    • CiNii Articles
  • Abstract License Flag
    Disallowed

Report a problem

Back to top